Research programme: stem cell therapeutics - BioRestorative Therapies

Drug Profile

Research programme: stem cell therapeutics - BioRestorative Therapies

Alternative Names: BRTX-100; brtxDISC; ThermoStem

Latest Information Update: 10 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator BioRestorative Therapies
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cardiovascular disorders; Diabetes mellitus; Hypertension; Intervertebral disc degeneration; Metabolic disorders; Obesity

Most Recent Events

  • 20 Apr 2017 BioRestorative Therapies has patents pending for covering methods related to methods of generating stem cells and stem cell lines from brown adipose tissue in Australia
  • 21 Mar 2017 BioRestorative Therapies has patents pending for human brown adipose derived stem cells in USA
  • 21 Mar 2017 BioRestorative Therapies files for patent protection for human brown adipose derived stem cells with Patent Cooperation Treaty and in Europe, Israel and Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top